US 11,892,454 B2
Method for the diagnosis of etoposide prodrug treatable cancer
Nalan Utku, Munich (DE)
Assigned to CELLACT PHARMA GMBH, Dortmund (DE)
Filed by CellAct Pharma GMBH, Dortmund (DE)
Filed on Aug. 23, 2018, as Appl. No. 16/110,007.
Application 16/110,007 is a continuation of application No. PCT/EP2017/054297, filed on Feb. 24, 2017.
Claims priority of application No. 16157179 (EP), filed on Feb. 24, 2016.
Prior Publication US 2019/0086418 A1, Mar. 21, 2019
Int. Cl. G01N 31/00 (2006.01); G01N 33/53 (2006.01); G01N 33/574 (2006.01); A61K 31/7048 (2006.01); C12Q 1/6886 (2018.01)
CPC G01N 33/57438 (2013.01) [A61K 31/7048 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57407 (2013.01); G01N 33/57419 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/918 (2013.01); G01N 2800/52 (2013.01)] 5 Claims
 
1. A method of stratifying and treating a patient suffering from biliary tract cancer (BTC), the method comprising the steps of
a) providing a BTC tumor sample of the patient,
b) determining the expression of carboxylesterase 2 (CES2) in the BTC tumor sample, wherein a lack of expression of CES2 in the BTC tumor sample indicates the risk of a patient that a treatment with an ester prodrug of a chemotherapeutic agent will not lead to a treatment success, and wherein the expression of CES2 in the BTC tumor sample indicates that a treatment with an ester prodrug of a chemotherapeutic agent will lead to a treatment success, and
c) (i) treating the patient whose BTC tumor sample is determined to express CES2 with the ester prodrug of a chemotherapeutic, or
(ii) treating the patient whose BTC tumor sample lacks CES2 expression with a treatment regimen that comprises a treatment that is different from the ester prodrug of a chemotherapeutic agent.